Evidence-Based Clinical Metric · Medically Reviewed November 2026

FIB-4 Calculator

The Fibrosis-4 index (FIB-4) combines age, AST, ALT, and platelet count into a single score that estimates the likelihood of advanced liver fibrosis. This calculator returns the score with its AASLD risk band for fatty liver disease (MASLD), the full working, and the limits that decide when the number can be trusted.

Disclaimer: This tool is for educational and clinical reference purposes only. It is not intended to replace professional medical judgment, diagnosis, or treatment. Active or severe acute symptoms require immediate emergency care.
Quick answer: FIB-4 = (age × AST) ÷ (platelets × √ALT). For a 55-year-old with AST 48 U/L, ALT 62 U/L, and platelets 180 ×10⁹/L: (55 × 48) ÷ (180 × 7.87) = 1.86 — indeterminate on the AASLD pathway, which calls for a second test such as a liver stiffness scan.

What the number describes

The result is a probability signal, not a measurement of scarring itself. Liver fibrosis is scar tissue that builds up after long-term liver injury; advanced fibrosis (stages F3–F4) is the point where the risk of cirrhosis and liver-related complications rises sharply. FIB-4 estimates how likely that stage is present, using four values that already appear on routine blood work, so no new test is needed to produce it.

FIB-4 is a screening step, not a verdict. A low score makes advanced fibrosis unlikely and a high score makes it likely enough to justify a second test, while a middle score settles nothing on its own. It sits beside the site's MELD score calculator, which grades the severity of liver disease once it is established, and the BUN to creatinine ratio calculator, which reads kidney function from the same kind of routine labs. For kidney filtration itself, the GFR calculator and the creatinine clearance calculator cover the renal side.

Age, liver enzymes & platelets

Calculate Your FIB-4

Enter age, AST, ALT, and platelet count from the same blood draw. The calculator shows the FIB-4 score, its AASLD risk band, and the working at each step.

Your details

How Is FIB-4 Calculated?

The calculator works in one formula with four inputs: age pushes the score up, AST pushes it up, ALT pulls it down through its square root, and platelets pull it down. The logic mirrors the biology: older age and higher AST track with more liver injury, while a falling platelet count tracks with portal hypertension as fibrosis advances. The square root on ALT keeps one very high ALT value from dominating the score the way a plain division would.

FIB-4 = (age [years] × AST [U/L]) ÷ (platelet count [×10⁹/L] × √ALT [U/L])

All four inputs come from the same blood draw, so the score can be recalculated whenever new labs arrive. The units matter: AST and ALT in U/L, platelets in ×10⁹/L (the count most laboratory reports show, often written as ×10³/µL with the same number). A platelet count reported in a different unit must be converted to ×10⁹/L before entry, or the score will be wrong by a factor of ten.

Variable table

ComponentClinical measurementReference rangeUnits
AgeAge in years at the time of the blood drawCalculator range: 18–90 years; validated mainly in adults 35–65years
ASTAspartate aminotransferase, a liver enzyme released when liver cells are injuredTypical laboratory range: 10–40 U/LU/L
ALTAlanine aminotransferase, a liver enzyme more specific to the liver than ASTTypical laboratory range: 7–45 U/LU/L
Platelet countPlatelets in blood; falls as fibrosis advances and the spleen traps plateletsTypical laboratory range: 150–400 ×10⁹/L×10⁹/L
FIB-4 score(Age × AST) ÷ (platelets × √ALT)Low risk below 1.30; high risk above 2.67 (AASLD pathway)Unitless

Only age, AST, ALT, and platelets enter the formula. Weight, sex, and other labs do not: that is the point of the score, which was built to run on the cheapest, most widely available results. For blood sugar over time, the site's HbA1c calculator converts the long-term glucose marker, and the BMI calculator covers the weight side of metabolic risk.

What Do the FIB-4 Bands Mean?

The bands below follow the AASLD 2023 practice guidance pathway for fatty liver disease (MASLD), the use case most people meet FIB-4 in today. They are risk bands for advanced fibrosis (stages F3–F4), not a staging result: the score estimates likelihood, and only a second test or biopsy stages fibrosis for certain.

AASLD risk bands (fatty liver disease pathway)

FIB-4 scoreBandWhat it means
Below 1.30Low riskAdvanced fibrosis unlikely. In the fatty liver study that set the cutoffs, a score of 1.30 or below had a 90% negative predictive value. The usual pathway is to repeat the score in 1–3 years and keep managing metabolic risk.
1.30 – 2.67IndeterminateAdvanced fibrosis neither ruled out nor confirmed. The usual pathway is a second-line test: a liver stiffness measurement (vibration-controlled transient elastography, often called a FibroScan) or the ELF blood test.
Above 2.67High riskAdvanced fibrosis likely. In the study that set the cutoffs, a score at or above 2.67 had an 80% positive predictive value. The usual pathway is review by a liver specialist, with elastography and further work-up.

The score is strongest at the low end. Ruling advanced fibrosis out is where FIB-4 earns its place as a first-line test: a low score spares most people a scan or a biopsy, while a high score concentrates the expensive tests on the people most likely to need them. The middle band is the honest limit of the test — about a third of people land there, and the score alone cannot sort them.

The original Sterling cutoffs (2006)

Sterling et al. (2006) developed FIB-4 in 555 training and 277 validation patients with HIV and hepatitis C coinfection, scoring fibrosis on the Ishak scale. Their operating points were different: below 1.45 to rule advanced fibrosis (Ishak stages 4–6) out, with a 90% negative predictive value and 70% sensitivity, and above 3.25 to rule it in, with a 97% specificity and 65% positive predictive value. Using those cutoffs, 87% of the 198 validation patients scoring outside 1.45–3.25 would have been classified correctly, and liver biopsy could have been avoided in 71% of the validation group.

SystemLow cutoffHigh cutoffPopulation and staging
Sterling et al. (2006), originalBelow 1.45Above 3.25HIV/HCV coinfection; Ishak stages 4–6
AASLD 2023 pathway (this calculator)Below 1.30Above 2.67Fatty liver disease (MASLD); advanced fibrosis F3–F4

The two sets are not interchangeable: they come from different populations and different staging scales. A score of 1.40 is low risk on the original cutoffs and indeterminate on the AASLD pathway. This calculator reports the AASLD bands because fatty liver disease is the main use today, and it lists the original cutoffs here so a result read against either system is not misread.

When Is the FIB-4 Score Less Reliable?

FIB-4 is a simple ratio built on four routine values. The limits below decide whether the number on this page is a useful screen or a misleading one.

  • Age under 35. The score rises with age by construction, and it was not validated in younger adults. In people under 35 it tends to under-estimate risk, so a low score in a young adult carries less reassurance than the same score in a 55-year-old.
  • Age over 65. The same age term pushes the score up in older adults, so it tends to over-estimate risk. The EASL 2024 guidance suggests a higher low-risk cutoff of 2.0 above age 65; the AASLD pathway keeps 1.30 and accepts more second-line tests in this group.
  • Acute illness and enzyme spikes. AST and ALT jump during acute hepatitis, a flare of chronic hepatitis, or a drug injury. A FIB-4 built on spiking enzymes reflects the flare, not the underlying fibrosis, and the AASLD guidance states the score is not for use in acutely ill patients.
  • Low platelets from other causes. Platelets fall for reasons that have nothing to do with the liver — immune thrombocytopenia, some medications, and bone marrow disorders among them. A low count from another cause inflates the score.
  • Alcohol-related liver disease. FIB-4 was validated mainly in viral hepatitis and fatty liver disease. Its operating points behave differently in alcohol-related disease, where AST often runs far above ALT.
  • FIB-4 does not measure fat or inflammation. The score reads fibrosis likelihood only. It says nothing about how much fat the liver holds or how active the inflammation is — the kidney and heart connection article on this site covers how metabolic disease links liver, kidney, and heart risk, and the eGFR by age article covers the kidney side of the same metabolic picture.
  • FIB-4 is not a liver biopsy. Even a high score is a probability, not a finding. Staging fibrosis for certain needs elastography, magnetic resonance elastography, or a biopsy, and the choice among them rests with the clinician reviewing the full picture.

When the score is not enough, the alternative is a second-line test: a liver stiffness measurement by elastography is the usual next step for an indeterminate or high score, reviewed with a clinician who can weigh the enzymes, the platelet trend, and the cause of the liver disease together.

Worked Example

A 55-year-old with AST 48 U/L, ALT 62 U/L, and platelets 180 ×10⁹/L enters the four values. The arithmetic is:

  • Square root of ALT: √62 = 7.87.
  • Numerator: 55 × 48 = 2,640.
  • Denominator: 180 × 7.87 = 1,417.3.
  • FIB-4: 2,640 ÷ 1,417.3 = 1.86 (1.8627 before rounding).
  • Band: indeterminate on the AASLD pathway (1.30–2.67).

The example matches the calculator exactly: the "Fill example" button loads age 55, AST 48, ALT 62, and platelets 180, and Calculate returns 1.86, indeterminate. A second check with a different body: a 42-year-old with AST 28, ALT 34, and platelets 240 gives (42 × 28) ÷ (240 × √34) = 1,176 ÷ 1,399.4 = 0.84, low risk. A third check: a 68-year-old with AST 92, ALT 58, and platelets 110 gives (68 × 92) ÷ (110 × √58) = 6,256 ÷ 837.7 = 7.47, high risk.

Frequently Asked Questions

What is FIB-4?

The Fibrosis-4 index, or FIB-4, is a simple score built from four routine results — age, AST, ALT, and platelet count — that estimates the likelihood of advanced liver fibrosis, the scarring that comes before cirrhosis. It was developed by Sterling et al. in 2006 for HIV and hepatitis C coinfection and is now used most often as a first-line screen in fatty liver disease (MASLD).

How is FIB-4 calculated?

Multiply age in years by AST in U/L, then divide by platelet count in 10⁹/L multiplied by the square root of ALT in U/L. For a 55-year-old with AST 48, ALT 62, and platelets 180: (55 × 48) ÷ (180 × √62) = 2,640 ÷ 1,417.3 = 1.86.

What is a good FIB-4 score?

Under the AASLD 2023 pathway for fatty liver disease, a FIB-4 below 1.30 is low risk for advanced fibrosis, 1.30 to 2.67 is indeterminate, and above 2.67 is high risk. A low score is reassuring because the test is strongest at ruling advanced fibrosis out; a high score points toward further testing rather than a confirmed result.

What does a FIB-4 above 2.67 mean?

A score above 2.67 sits in the high-risk band of the AASLD pathway: in the fatty liver study that set the cutoffs, about 80% of people scoring at or above 2.67 had advanced fibrosis. It is a prompt for a second test, such as a liver stiffness scan or elastography, and review by a liver specialist — not a confirmed finding on its own.

How accurate is FIB-4?

In the fatty liver validation by Shah et al. (2009), FIB-4 had an AUROC of 0.802 for advanced fibrosis, better than seven other noninvasive markers in the same study. A score of 1.30 or below had a 90% negative predictive value, so it is strongest at ruling advanced fibrosis out. Accuracy falls at the extremes of age and when liver enzymes spike during acute illness.

Why are there two sets of FIB-4 cutoffs?

Sterling et al. (2006) set the original cutoffs at 1.45 and 3.25 for Ishak fibrosis stages in HIV and hepatitis C coinfection. Later work in fatty liver disease, adopted by the AASLD 2023 guidance, uses 1.30 and 2.67. The two sets come from different populations and different staging scales, so they are not interchangeable — this calculator reports the AASLD bands and lists the original cutoffs for reference.

Sources and Editorial Review

Reviewed by the Heart Score Calculator Editorial Team, November 2026. The method, risk bands, and limits on this page follow the sources below.

  1. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. DOI: 10.1002/hep.21178
  2. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; NASH Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2009;7(10):1104-1112. DOI: 10.1016/j.cgh.2009.05.033
  3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. DOI: 10.1097/HEP.0000000000000323

Related tools on this site: the MELD score calculator grades liver disease severity once it is established, the BUN to creatinine ratio calculator reads kidney function from routine labs, the GFR calculator estimates kidney filtration, the HbA1c calculator converts long-term blood sugar, and the medical calculators hub lists every clinical tool on the site.